Targeted Genetics Receives Nasdaq Notification
26 4월 2008 - 9:00AM
Marketwired
SEATTLE, WA today announced that it received a staff deficiency
letter from the Nasdaq Stock Market on April 23, 2008 indicating
that, for the last 30 consecutive business days, the bid price of
Targeted Genetics' common stock has closed below the minimum $1.00
per share requirement for continued listing under Marketplace Rule
4310(c)(4).
The letter stated that under Marketplace Rule 4310(c)(8)(d),
Targeted Genetics will be provided with 180 calendar days, or until
October 20, 2008, to regain compliance with Marketplace Rule
4310(c)(4). To regain compliance, anytime before October 20, 2008,
the bid price of Targeted Genetics' common stock must close at
$1.00 per share or more for a minimum of 10 consecutive business
days.
On October 20, 2008, if Targeted Genetics meets The Nasdaq
Capital Market initial inclusion criteria set forth in Marketplace
Rule 4310(c), except for the bid price requirement, it may be
provided with an additional 180 calendar day compliance period to
demonstrate compliance. If Targeted Genetics is not eligible for an
additional compliance period at that time, Nasdaq Staff will
provide written notification that Targeted Genetics' securities
will be delisted. Upon such notice, Targeted Genetics may appeal
the Nasdaq Staff's Determination to a Listing Qualifications Panel,
pursuant to the procedures set forth in the Nasdaq Marketplace Rule
4800 Series. There can be no assurance that, if Targeted Genetics
does appeal the Nasdaq Staff's Determination that such appeal would
be successful.
About Targeted Genetics
Targeted Genetics Corporation is a biotechnology company
committed to the development of innovative targeted molecular
therapies for the prevention and treatment of acquired and
inherited diseases with significant unmet medical need. Targeted
Genetics' proprietary Adeno-Associated Virus (AAV) technology
platform allows it to deliver genes that encode proteins to
increase gene function or RNAi to decrease or silence gene
function. Targeted Genetics' product development efforts target
inflammatory arthritis, AIDS prophylaxis, congestive heart failure
and Huntington's disease. To learn more about Targeted Genetics,
visit Targeted Genetics' website at www.targetedgenetics.com.
Investor and Media Contact: Stacie D. Byars WeissComm Partners
415.946.1072 Email Contact Carolyn Wang WeissComm Partners
415.946.1065 Email Contact
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
